Literature DB >> 10219961

Effect of NMDA antagonists on the activity of glutaminase and aspartate aminotransferase in the developing rat cerebellum.

J Moran1, S Alavez, M Rivera-Gaxiola, A Valencia, S Hurtado.   

Abstract

Chronic treatment of rats from postnatal day 6 to 25 with drugs that interact with the N-methyl-D-aspartate (NMDA) receptor induced a differential effect on the activity of some enzymes involved in neurotransmitter synthesis. Two of these drugs ((5R,10S)-(+)-5-methyl-10,11 -dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate (MK-801) and 3-(2-carboxypiperazin-4-yl)propyl-1phosphonic acid (CPP)) caused a marked reduction (20-40%) of glutaminase and aspartate aminotransferase activity in the cerebellum. These changes were observed only at a very precise time of development (i.e. 10 to 19 postnatal day). The competitive antagonist, amino phosphonovaleric acid (APV), did not affect any of the enzymes studied at all tested ages. When animals were treated with NMDA only a slight, but significant, increase in the activity of glutaminase was observed at 9-11 postnatal day only. Any of the agonists or antagonists tested significantly affected the activity of lactate dehydrogenase as compared to control animals. Histologic observations of cerebella treated with the indicated drugs showed that only MK-801, and CPP to a lesser extent, induced a small reduction in the width of the internal granule layer. The body weight of animals treated with MK-801 was clearly reduced, but only in more mature rats (> 16 postnatal day), when animals did not show any alteration in the enzymes tested. These results support the suggestion that presynaptic influences, particularly from glutamatergic neurons, are critical to promote cerebellar granule neurons differentiation during critical periods of the cerebellar development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219961     DOI: 10.1016/s0736-5748(98)00063-x

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  7 in total

1.  Biochemical and structural characterization of mouse mitochondrial aspartate aminotransferase, a newly identified kynurenine aminotransferase-IV.

Authors:  Qian Han; Howard Robinson; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

2.  Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

Authors:  Lidia Glodzik; Kevin G King; Oded Gonen; Songtao Liu; Susan De Santi; Mony J de Leon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-02-07       Impact factor: 5.067

Review 3.  Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Cell Mol Life Sci       Date:  2009-10-15       Impact factor: 9.261

4.  Apolipoprotein E acts at pre-synaptic sites...among others.

Authors:  Steven W Barger
Journal:  J Neurochem       Date:  2012-09-28       Impact factor: 5.372

Review 5.  Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain.

Authors:  E Kvamme; B Roberg; I A Torgner
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 6.  Glutamate dehydrogenase in brain mitochondria: do lipid modifications and transient metabolon formation influence enzyme activity?

Authors:  Mary C McKenna
Journal:  Neurochem Int       Date:  2011-07-13       Impact factor: 3.921

7.  Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner.

Authors:  Josephe A Honorat; Yuji Nakatsuji; Mikito Shimizu; Makoto Kinoshita; Hisae Sumi-Akamaru; Tsutomu Sasaki; Kazushiro Takata; Toru Koda; Akiko Namba; Kazuya Yamashita; Eri Sanda; Manabu Sakaguchi; Atsushi Kumanogoh; Takashi Shirakura; Mizuho Tamura; Saburo Sakoda; Hideki Mochizuki; Tatsusada Okuno
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.